ArticleCommunications biology2022
Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling.iScience · 2026Article
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
- Shared HLA-E and Mamu-E Peptide Repertoires With Subtle Peptide Binding Differences Revealed by Combined nDSF- and Fluorescence Polarisation-Based Methods.European journal of immunology · 2026Article
- A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Chimeric Antigen Receptor Cell Therapy: Current Status and Its Potential in Aging and Alzheimer's Disease.International journal of molecular sciences · 2025Review
- CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.Immunotherapy advances · 2025Article
- HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.Immunological reviews · 2025Review
- HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.Frontiers in immunology · 2025Article
- Article
- NK cell-based tumor immunotherapy.Bioactive materials · 2024Review
- Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.Journal of cancer research and clinical oncology · 2023Article
- Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics.Biomaterials research · 2023Review
- Human leukocyte antigen and tumor immunotherapy (Review).International journal of oncology · 2023Review
- Review
- Delivery ofFrontiers in immunology · 2023Article
- Co-expression of HLA-E and HLA-G on genetically modified porcine endothelial cells attenuates human NK cell-mediated degranulation.Frontiers in immunology · 2023Article
- Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer.Vaccines · 2022Review
- Implications of NKG2A in immunity and immune-mediated diseases.Frontiers in immunology · 2022Review
- Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies.Frontiers in immunology · 2022Article
- The Potential Role of Expression of HLA-E and HLA-G in Organ Xenotransplantation.XenotransplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 3 countries.
Dapeng Li *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0002-8131-5914
Simon Brackenridge *Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.ORCID http://orcid.org/0000-0002-0587-7560
Lucy C Walters *Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.
Olivia SwansonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0001-8162-8358
Karl HarlosDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.ORCID http://orcid.org/0000-0002-7266-4354
Daniel RozbeskyDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
Derek W CainDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Richard M ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Zekun MuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0003-4093-8346
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Max QuastelNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.ORCID http://orcid.org/0000-0001-6551-4713
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0003-4446-1194
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Wes RountreeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0001-7399-7954
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK.ORCID http://orcid.org/0000-0002-3877-9780
E Yvonne JonesDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.ORCID http://orcid.org/0000-0002-3834-1893
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Mihai L AzoiteiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. mihai.azoitei@duke.edu.ORCID http://orcid.org/0000-0002-4080-1350
Geraldine M GillespieNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. geraldine.gillespie@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-1075-870X
Andrew J McMichaelNuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7FZ, UK. andrew.mcmichael@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-9101-7478
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. barton.haynes@duke.edu.ORCID http://orcid.org/0000-0002-7643-9023
Duke University · USUniversity of Oxford · GBCentre for Human Genetics · GBNuffield Orthopaedic Centre · GB
Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MMedical Research Council MR/T000503/1NIAID NIH HHS P30 AI064518NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164567
Abstract
The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A
Indexed as
Cytotoxicity, ImmunologicHistocompatibility Antigens Class IAnimalsHLA AntigensHLA-E AntigensHumansImmunoglobulinsKiller Cells, NaturalMicePeptidesProtein Sorting SignalsHistocompatibility Antigens Class IHLA AntigensHLA-E AntigensImmunoglobulinsPeptidesProtein Sorting Signals
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.